胸腺肽α1注射剂联合恩替卡韦胶囊治疗肝硬化肝功能代偿期的临床研究

发布时间：2019-01-24 11:44

【摘要】：目的观察胸腺肽α1注射剂联合恩替卡韦胶囊治疗肝硬化肝功能代偿期患者的临床疗效及安全性。方法将80例乙型病毒性肝炎(乙肝)e抗原(HBe Ag)阳性肝硬化肝功能代偿期患者随机分为对照组40例和试验组40例。对照组予以恩替卡韦0.5 mg,qd,口服;试验组在对照组治疗的基础上,予以胸腺肽α1 1.6 mg,biw,皮下注射。2组患者均治疗24周。比较2组患者的临床疗效、谷丙转氨酶、谷草转氨酶、总胆红素、HBV-DNA和HBe Ag转阴率以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.50%(37/40例)和75.00%(30/40例),差异有统计学意义(P0.05)。治疗后,试验组与对照组的谷丙转氨酶分别为(51.39±8.17),(64.12±6.24)U·L~(~(-1));谷草转氨酶分别为(33.49±5.14),(40.05±5.28)U·L~(~(-1));总胆红素分别为(17.59±1.59),(16.32±1.32)mmol·L~(~(-1));HBV-DNA转阴率分别为77.50%,40.00%;HBe Ag转阴率分别为70.00%,32.50%;HBe Ag/抗HBe转换率为35.00%,22.50%,差异均有统计学意义(均P0.05)。试验组发生的药物不良反应有恶心呕吐和头晕,对照组发生的药物不良反应有恶心呕吐、头晕和过敏。试验组和对照组的药物不良反应发生率分别为7.50%和17.50%,差异有统计学意义(P0.05)。结论胸腺肽α1注射剂联合恩替卡韦胶囊治疗HBeAg阳性肝硬化肝功能代偿期的临床疗效确切,且安全性较高。
[Abstract]:Objective to observe the efficacy and safety of thymosin 伪 1 injection combined with entecavir capsule in the treatment of liver cirrhosis patients with compensatory liver function. Methods 80 patients with hepatitis B (hepatitis B) e antigen (HBe Ag) positive liver function compensation were randomly divided into control group (n = 40) and experimental group (n = 40). The control group was given entecavir 0.5 mg,qd, and the experimental group was subcutaneously injected with thymosin 伪 11.6 mg,biw, on the basis of treatment in the control group. The patients in both groups were treated for 24 weeks. The clinical efficacy, alanine aminotransferase, total bilirubin, HBV-DNA and HBe Ag negative rate and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 92.50% (37 / 40 cases) and 75.00% (30 / 40 cases), respectively. The difference was statistically significant (P0.05). After treatment, the levels of alanine aminotransferase in the experimental group and the control group were (51.39 卤8.17), (卤6.24) U L ~ (-1);, respectively. Glutamic oxaloacetic transaminase was (33.49 卤5.14), (40.05 卤5.28) U L ~ (-1); total bilirubin was (17.59 卤1.59), (16.32 卤1.32) mmol L ~ (-1);, respectively. The conversion rate of HBV-DNA to HBe Ag was 77.50 and 77.50, respectively. The conversion rate of HBe Ag/ to HBe was 35.00 and 22.50, respectively. The difference was statistically significant (P0.05). Adverse drug reactions in the trial group were nausea, vomiting and dizziness, and in the control group, nausea and vomiting, dizziness and allergy. The incidence of adverse drug reactions in test group and control group was 7.50% and 17.50% respectively, the difference was statistically significant (P0.05). Conclusion Thymosin 伪 1 injection combined with entecavir capsule is effective and safe in the treatment of HBeAg positive liver cirrhosis.
【作者单位】：南阳市中心医院消化内科;郑州大学第一附属医院感染科;
【基金】：河南省科技攻关计划基金资助项目(201303062)
【分类号】：R575.2

【相似文献】